ArticleBiology2026
Immune-Metabolic Profiling Reveals Functional Heterogeneity Within Colorectal Cancer Consensus Molecular Subtypes.
Sergio Madurga, David López-Blanco, Carles Foguet, Sara Lahoz, Helena Oliveres, Reinaldo Moreno, Teresa Gorria, Leire Pedrosa, Silvia Marin, Mariam Rojas and 4 more
Abstract read
In one paragraphArticle in Biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from itWhat it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
14 authors.
Sergio MadurgaDepartment of Material Science and Physical Chemistry and Research Institute of Theoretical and Computational Chemistry of University of Barcelona (IQTCUB), Universitat de Barcelona, 08028 Barcelona, Spain.ORCID 0000-0002-8135-7057 David López-BlancoCentro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Instituto de Salud Carlos III (ISCIII), 28029 Madrid, Spain.
Carles FoguetBritish Heart Foundation Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge CB2 0SR, UK.
Sara LahozCentro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Instituto de Salud Carlos III (ISCIII), 28029 Madrid, Spain.
Helena OliveresTranslational Genomics and Targeted Therapeutics in Solid Tumors Group, IDIBAPS, Medical Oncology Department, Hospital Clínic of Barcelona, Universitat de Barcelona, 08036 Barcelona, Spain.ORCID 0000-0003-1801-1181 Reinaldo MorenoTranslational Genomics and Targeted Therapeutics in Solid Tumors Group, IDIBAPS, Medical Oncology Department, Hospital Clínic of Barcelona, Universitat de Barcelona, 08036 Barcelona, Spain.
Teresa GorriaTranslational Genomics and Targeted Therapeutics in Solid Tumors Group, IDIBAPS, Medical Oncology Department, Hospital Clínic of Barcelona, Universitat de Barcelona, 08036 Barcelona, Spain.
Leire PedrosaTranslational Genomics and Targeted Therapeutics in Solid Tumors Group, IDIBAPS, Medical Oncology Department, Hospital Clínic of Barcelona, Universitat de Barcelona, 08036 Barcelona, Spain.ORCID 0000-0002-1852-4975 Silvia MarinCentro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Instituto de Salud Carlos III (ISCIII), 28029 Madrid, Spain.ORCID 0000-0003-0693-2207 Mariam RojasTranslational Genomics and Targeted Therapeutics in Solid Tumors Group, IDIBAPS, Medical Oncology Department, Hospital Clínic of Barcelona, Universitat de Barcelona, 08036 Barcelona, Spain.
Jordi CampsCentro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Instituto de Salud Carlos III (ISCIII), 28029 Madrid, Spain.ORCID 0000-0003-2929-4228 Francesc MasDepartment of Material Science and Physical Chemistry and Research Institute of Theoretical and Computational Chemistry of University of Barcelona (IQTCUB), Universitat de Barcelona, 08028 Barcelona, Spain.ORCID 0000-0002-1362-4002 Joan MaurelCentro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Instituto de Salud Carlos III (ISCIII), 28029 Madrid, Spain.ORCID 0000-0002-9413-5592 Marta CascanteCentro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Instituto de Salud Carlos III (ISCIII), 28029 Madrid, Spain.ORCID 0000-0002-2062-4633 Funding
Biomedical Research Network Center for Liver and Digestive Diseases CB06/04/0016Biomedical Research Network Center for Liver and Digestive Diseases CB17/04/00023Catalan Agency for the Management of University and Research Grants (AGAUR) 2021- SGR-00350Catalan Agency for the Management of University and Research Grants (AGAUR) 2021-SGR-01328Fundación Olga Torres Modalitat A.2019/2020Institució Catalana de Recerca i Estudis Avançats ICREA-Academia-2021Ministry of Science, Innovation and Universities FPU21/01937Ministry of Science, Innovation and Universities PI19/00740Ministry of Science, Innovation and Universities PI20/00863Ministry of Science, Innovation and Universities PID2023-150539OB-I00Spanish Association Against Cancer ROYE19040POST_001Spanish Structures of Excellence María de Maeztu CEX2021-001202-M
6 · The paper itselfAbstract
The Consensus Molecular Subtype (CMS) classification provides a widely used transcriptomic framework for colorectal cancer (CRC) stratification with clear prognostic and therapeutic relevance. However, it does not fully capture the immune-metabolic heterogeneity underlying tumor-microenvironment interactions within each subtype. Here, we integrate a validated immune-metabolic gene signature as a functional layer to refine CMS classification and systematically characterize diversity across CMS1-4 tumors. Using transcriptomic data from 2918 CRC samples across three independent cohorts (GSE1, TCGA, and GSE2), we show that CMSs display robust yet distinct immune-metabolic distributions across datasets. CMS4 tumors exhibit glycolytic, stromal-dependent, and immunosuppressive profiles, whereas CMS2 and CMS3 are enriched in oxidative and metabolically flexible states. Importantly, CMS1 tumors segregate into two major immune-metabolic profiles, revealing marked heterogeneity within this immune-activated subtype. These patterns are preserved in metastatic samples, supporting their stability across disease stages. Overall, integrating immune-metabolic profiling into CMSs reveals previously unrecognized functional heterogeneity and provides a refined framework to interpret tumor-microenvironment states. This approach facilitates the identification of context-specific metabolic vulnerabilities with potential clinical relevance.
Indexed as
cancer metabolismcolorectal cancerConsensus Molecular Subtypes (CMS)IMMETCOLSimmune–metabolic profilingtranscriptomicstumor heterogeneitytumor microenvironment
Identifiers
PMID42510676
PMCPMC13403527
What Socratic holds
Textmetadata
LicenceCC BY
Read underepoch 390